TET2 is primarily responsible for catalyzing the conversion of m5C to hm5C, thereby facilitating the removal of m5C modifications in RNA.286 Studies have measured TET2 expression across a spectrum of cancer types, revealing its upregulation in patients with low-grade glioma.287 In contrast, TET2 expression is reduced in clear cell renal cell carcinoma (ccRCC), ovarian cancer, and prostate adenocarcinoma.288,289 The specific role of TET3 in mediating m5C elimination remains to be fully elucidated. Here, TET2 is linked to nonpapillary renal cell carcinoma.